-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Category Archives: Public Policy
Latest From Public Policy
Measuring the Impact of Innovation
By Joe Allen, President, Allen and Associates It’s always an indication of interest and importance in a topic when a panel draws a standing room only crowd. And that was the case with the Measuring the Impacts of Innovation: What is the Future of Tech Transfer? session at the 2012 BIO International Convention. The panel focused on the need to help policy makers, institutions and the public identify appropriate measures for how publicly funded R&D Read More >
Gene Patent Discussion Should Include Industrial, Environmental, & Ag Biotech
Twenty-three industrial and agricultural biotech companies, ranging from development-stage businesses to all of the largest players in the field, sent a letter to the Solicitor General expressing concern over the pending appeal in the Myriad “gene patents” case. The companies wrote the letter to correct the myopic view that this case is only about human genetic diagnostics. The case could potentially adversely impact agricultural and industrial biotechnology, whose activities are far removed from the clinical Read More >
2012 BIO International Convention: Academic and Tech Transfer Community
Universities have historically been on the front lines of translating innovative research into novel medicines and technologies useful to patients. With that in mind, the 2012 BIO International Convention will look to highlight the role of academia in the advancement of the biotechnology field through the BIO Academic Park and the Translational Research Forum. Hosted by the Biotechnology Industry Organization (BIO), this year’s global event for biotechnology will take place June 18-21, 2012 at the Read More >
IP Creates Jobs for America
By Mark Elliot, Executive Vice President, U.S. Chamber of Commerce’s Global Intellectual Property Center In May, the Global Intellectual Property Center (GIPC) was proud to unveil the results of our state intellectual property (IP) jobs research, which has been a year in the making. The study, IP Creates Jobs for America, provides real, tangible evidence that the economic benefits of IP are broad and far-reaching. In looking at a variety of government data on intellectual Read More >
Mayo v. Prometheus: Thought Leaders Express Concern and Evaluate the Impact
The Mayo v. Prometheus event hosted at George Washington School of Law with the Biotechnology Industry Organization created an opportunity for a panel of thought leaders to distill meaning from the case, the impact on personalized medicine, and possible solutions to the Court created problem.* Is the decision a game-changer? Judge Paul R. Michel, former Chief Judge of the Court of Appeals for the Federal Circuit handling patent cases, concluded that the Mayo v. Prometheus Read More >
